Loading clinical trials...
Loading clinical trials...
Phase II Trial of Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in the Treatment of Patients With Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.
Upon determination of eligibility, patients will receive: * Ifosfamide + Carboplatin + Etoposide + Rituximab Patients showing no response to this combination regimen will receive 90Y Zevalin after two cycles or when progression is clearly documented. In responding patients, four cycles will be administered, followed by 90Y Zevalin.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Start Date
October 1, 2003
Primary Completion Date
August 1, 2005
Completion Date
August 1, 2005
Last Updated
May 3, 2011
40
Estimated participants
Ifosfamide
DRUG
Carboplatin
DRUG
Etoposide
DRUG
Rituximab
DRUG
90Y Zevalin
DRUG
Lead Sponsor
SCRI Development Innovations, LLC
Collaborators
NCT04188678
NCT00739141
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions